Marshall Wace
CBAY

Marshall Wace’s Cymabay Therapeutics CBAY Stock Holding History

Marshall Wace’s Portfolio CBAY Stock Details CBAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-158,411
Closed -$2.36M – 2855
2023
Q3 		$2.36M Sell
158,411
-623,324
-80% -$8.26M 0.01% 1151
2023
Q2 		$8.56M Buy
781,735
+538,554
+221% +$5.01M 0.02% 803
2023
Q1 		$2.12M Buy
243,181
+161,401
+197% +$1.29M 0.01% 1423
2022
Q4 		$513K Buy
+81,780
New +$311K ﹤0.01% 2358
2022
Q3 		– Sell
-11,000
Closed -$33K – 4155
2022
Q2 		$33K Buy
+11,000
New +$26.3K ﹤0.01% 3345
2019
Q2 		– Sell
-63,589
Closed -$844K – 1955
2019
Q1 		$844K Buy
63,589
+9,231
+17% +$98.2K 0.01% 989
2018
Q4 		$428K Buy
+54,358
New +$517K ﹤0.01% 1158

Other funds holding CBAY

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
PA
Perceptive Advisors New York $5.06B AUM 314.02% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return